Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Current Cardiology Reports

Volumn 3, Issue 5, 2001, Pages 362-370

  Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN;

CHEMICALLY INDUCED DISORDER; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANCROD; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARINOIDS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOPENIA;

EID: 0035458372     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0052-7     Document Type: Article

References (50)

1. Fahey VA: Heparin-induced thrombocytopenia. J Vasc Nurs 1995, 13:112-11
2. Brieger DB, Mak KH, Kottke-Marchant K, et al.: Heparininduced thrombocytopenia. J Am Coll Cardiol 1998, 31:1449-1459.
3. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995, 332:1374-1376.
4. Eikelboom JW, Anand SS, Mehta SR, et al.: Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome with ST elevation: Organization to assess strategies for ischemic syndromes (OASIS-2) Study. Circulation 2001, 103:643-650.
5. McClure MW, Berkowitz SD, Sparapani R, et al.: Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the PURSUIT trial experience. Circulation 1999, 99:2892-2900.
6. Berkowitz SD, Sparapani RA, Califf RM, et al.: Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998, 32:387-392.
7. Kaplan KL, Broekman MJ, Chernoff A, et al.: Platelet alpha granule proteins: studies on release and subcellular localization. Blood 1979, 53:604-608.
8. Amiral J, Bridey F, Dreyfus M, et al.: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparininduced thrombocytopenia. Thromb Haemost 1992, 68:95-96.
9. Amiral J, Wolf M, Fisher AM, et al.: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996, 92:954-959.
10. Amiral J, Marfaing-Koka A, Wolf M, et al.: Presence of autoantibodies to interleukin-8 or neutrophil activating peptide-2 in patients with heparin associated thrombocytopenia. Blood 1996, 88:410-416.
11. Chong BH, Fawaz I, Chesterman CN, et al.: Heparin induced thrombocytopenia: mechanism of interaction of the heparin dependent antibody with the platelets. Br J Haematol 1989, 73:235-240.
12. Rubinstein E, Boucheix C, Worthington RE, et al.: Anti-platelet antibody interactions with the Fcy receptor. Semin Thromb Hemost 1995, 21:10-22.
13. Burgess JK, Lindeman R, Chesterman CN, et al.: Single amino acid mutation of Fcy receptor is associated with the development of heparin induced thrombocytopenia. Br J Haematol 1995, 91:761-766.
14. Visentin GP, Ford SE, Scott JP, et al.: Antibodies from patients with heparin induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93:81-88.
15. Wallis DE, Workman DL, Lewis BE, et al.: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635.
16. Antman EM, Cohen M, Radley D, et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI-11B-ESSENCE metaanalysis. Circulation 1999, 100:1602-1608.
17. Ramakrishna R, Manoharan A, Kwan YL, et al.: Heparin induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Organon). Br J Haematol 1992, 91:736-738.
18. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993, 70:554-561.
19. Tardy-Poncet B, Tardy B, Reynaud J, et al.: Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999, 115:1616-1620.
20. Hale LP, Smith K, Braden GA, et al.: Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1998, 45:318-322.
21. Cantor WJ, Leblanc K, Garvey B, et al.: Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin. Cathet Cardiovasc Intervent 1999, 46:352-355.
22. Demers C, Ginsberg JS, Brill-Edwards P, et al.: Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991, 78:2194-2197.
23. Cole CW, Fournier LM, Bormanis J: Heparin associated thrombocytopenia and thrombosis: optimum therapy with ancrod. Can J Surg 1990, 33:207-210.
24. Haas S, Walenga JM, Jeske WP, et al.: Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999, 25(Suppl 1):67-75.
25. Polgar J, Eichler P, Greinacher A, et al.: Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparininduced thrombocytopenia patients. Blood 1998, 91:549-554.
26. The ESPRIT Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation: a randomised placebo controlled trial. Lancet 2000, 356:2037-2044.
27. The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998, 352:87-92.
28. Walenga JM, Jeske WP, Wallis DE, et al.: Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999, 25(suppl 1):77-81.
29. Jeske WP, Walenga JM, Szatkowski E, et al.: Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997, 88:271-281.
30. Jeske WP, Mousa SA, Yang LG: Short-acting glycoprotein IIb/IIIa inhibitors may be safer for the management of patients with active heparin induced thrombocytopenic syndrome. Blood 1998, 92:181A.
31. Hursting MJ, Alford KL, Becker JP, et al.: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997, 23:503-516.
32. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997, 23:197-202.
33. Fenton JW II, Villanueva GB, Ofosu FA, et al.: Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis 1991, 21:27-31.
34. Eichler P, Heinz-Juergen F, Lubenow N, et al.: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000, 96:2373-2378.
35. Maraganore JM, Adelman BA: Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coronary Artery Disease 1996, 7:438-448.
36. Lewis BE, Wallis DE, Berkowitz SD, et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
37. Matthai WH, Jr.: Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999, 25(suppl 1):57-60.
38. Lewis BE, Matthai W, Grassman ED, et al.: Results of Phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT). Circulation 1997, 96:I217.
39. Greinacher A, Volpel H, Janssens U, et al.: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999, 99:73-80.
40. Greinacher A, Janssens U, Berg G, et al.: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100:587-593.
41. Campbell KR, Mahaffey KW, Lewis BE, et al.: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000, 12(suppl F):14F-19F.
42. Anand S, Yusuf S, Pogue J, et al.: Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation 1998, 98:1064-1070.
43. The OASIS-2 Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999, 353:429-438.
44. Antman EM: Hirudin in acute myocardial infarction-thrombolysis and thrombin in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
45. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775-782.
46. Serruys PW, Herrman JPR, Simon R, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757-763.
47. Topol EJ, Bonan R, Jewitt D, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629.
48. Bittl JA, Strony J, Brinker JA, et al.: Treatment with bivalirudin (HIRULOG) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764-769.
49. Bittl JA, Chaitman BR, Feit F: Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 (in press).
50. Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.